Gilead Sciences ($GILD) and its hep C juggernaut kept rolling in Q4, churning out street-beating sales of $4.9 billion. But it took strong growth overseas to overcome an expected falloff for Sovaldi and Harvoni in the U.S. While Gilead execs say there's lots of growth left in the hep C market, they acknowledged Tuesday that the company needs to be looking for M&A opportunities in areas such as oncology. Report
> Sun Pharmaceuticals discounted its new copycat version of Novartis' ($NVS) Gleevec by 30% to the brand, hoping to make big inroads in the market for leukemia treatments. Report
> AstraZeneca's ($AZN) Tagrisso (osimertinib) won expedited European approval for EGFR-positive advanced non-small cell lung cancer; it was approved by the U.S. FDA in November. Release
> China fined 5 domestic drugmakers almost 4 million yuan ($608,000) for price-fixing, saying they colluded to support the price of allopurinol, used to treat gout and kidney disease. Report
> The AIDS Healthcare Foundation sued Gilead Sciences ($GILD), accusing the company of holding back its next-gen TAF drug--now on its way to FDA approval--to allow a previous drug, tenofovir, to reap more sales. Report
And Finally... Teen girls with Type 1 diabetes are at higher risk of an eating disorder, with some skipping insulin doses to lose weight. Report